1-4 of 4
Micah M. Burch
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study

Jessica K. Altman, Jamie Koprivnikar, James K McCloskey, Vamsi Kota, Michael Keng, Dale L. Bixby, Olga Frankfurt, Ashkan Emadi, Tsila Zuckerman, Micah M. Burch, Moshe Y. Levy, Selina M. Luger, Bhavana Bhatnagar, Ofir Wolach, Chezi Ganzel, Mary-Beth M. Percival, Gail J. Roboz, Michael Craig, Itai Levi, Anna Gourevitch, Liat Flaishon, Darrel P. Cohen, Shoshi Tessler, Chen Blumberg, Stela Gengrinovitch, Ruth Ben Yakar, Jacob M. Rowe
Journal: Blood
Blood (2021) 138 (Supplement 1): 1273.
https://doi.org/10.1182/blood-2021-149361
Published: 2021
Journal Articles

Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation

Jessica K. Altman, MD, Selina M. Luger, MD FRCPC, Olga Frankfurt, MD, Tsila Zuckerman, MD, Jamie L. Koprivnikar, MD, Vamsi Kota, MD, Ashkan Emadi, MD, PhD, Bhavana Bhatnagar, DO, Dale L. Bixby, MD, Micah M. Burch, MD, Ofir Wolach, MD, Itai Levi, MD, Anna Gourevitch, MD, Ron Ram, MD, Liat Flaishon, PhD MD, Shoshi Tessler, PhD, Stela Gengrinovitch, PhD, Ruth Ben Yakar, PhD, Jacob M. Rowe, MB, BS
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–10.
https://doi.org/10.1182/blood-2020-139136
Published: 2020
Journal Articles

Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integrated Results from a Phase 1/2a and an Ongoing Phase 2b

Jessica K. Altman, Tsila Zuckerman, MD, Olga Frankfurt, MD, Selina M. Luger, MD FRCPC, Dale L. Bixby, MD, Vamsi Kota, MBBS, Micah M. Burch, Ofir Wolach, Itai Levi, MD, Anna Gourevitch, Ron Ram, MD, Liat Flaishon, Shoshi Tessler, Stela Gengrinovitch, Ruth Ben Yakar, Jacob M. Rowe, MB, BS
Journal: Blood
Blood (2019) 134 (Supplement_1): 179.
https://doi.org/10.1182/blood-2019-124330
Published: 2019
Journal Articles

Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients with MYC Alterations

Daniel J. Landsburg, MD, Radhakrishnan Ramchandren, MD, Amir Hafeez, MD, Robert Gharavi, PharmD, Tania Chander, PharmD, Anna Ma, MS, Micah M. Burch, MD, Yasuhiro Oki, MD
Journal: Blood
Blood (2016) 128 (22): 5422.
https://doi.org/10.1182/blood.V128.22.5422.5422
Published: 2016